Page 12 - Dr Reddy's Laboratories

Dr Reddy's launches Plaquenil's generic version in US after USFDA clearance

The tablets are available in 200 mg in the bottle count sizes of 100 and 500

Dr Reddy's launches anti-epilepsy drug in US, taps into $37 mn market

The drug has been approved by the US Food and Drug Administration

US court restrains Dr Reddy's from selling generic variant of Suboxone

The court has scheduled an expedited hearing of the preliminary injection for Thursday (June 28) and a ruling is expected soon after

Dr Reddy's generic opioid addiction drug launch faces court hurdle in US

Dr Reddy's recently announced the launch of Buprenophine and Naloxone Sublingual Film, a generic equivalent of Suboxone

Dr Reddy's gains 3% on USFDA nod for launch of generic version of Suboxone

In past eight trading sessions, the stock of pharmaceutical company has rallied 20% from Rs 1,960 on June 5, 2018, as compared to 2% rise in the S&P BSE Sensex.

Dr Reddy's gains 4% as API Srikakulam plant gets USFDA clearance

The stock was up nearly 4% to Rs 2,010 on the BSE in early morning trade after the company said the US health regulator has completed the audit of its API Srikakulam plant (SEZ) with no observations.

Dr Reddy's names ex-Teva official Erez Israeli as COO, global generics head

BS ReporterHyderabad, 29 March. Dr Reddy's Laboratories Limited today announced a change in the senior leadership team. The company has appointed former president and CEO of Enzymotec, Erez Israeli as the chief operating officer and global head of generics and PSAI(pharmaceutical services and active ingredients).He will replace Abhijit Mukherjee, who is retiring on March 31, 2018 after a 15-year stint in Dr Reddy's. In a career spanning 25 years, Israeli has held leadership positions that have contributed significantly to the performance of companies he worked for, Dr Reddy's said. Prior to Enzymotec, he completed 23 years with Teva Pharmaceuticals Limited, where he held several positions of responsibility including vice president, marketing and sales for North America, vice president Asia Operations, President Teva API, group executive vice president, head of global quality, and president and CEO growth markets.Israeli will join the company on April 2. He will report to Dr Reddy's ...

Dr Reddy's gets 5 observations from US FDA for API unit at Hyderabad

The company said plant-3 at Bollaram on the city outskirts has recieved these observations upon completion of an inspection

Dr Reddy's chairman, COO added as defendants in US class action lawsuit

The company believes that the asserted claims are without merit and intends to vigorously defend itself against the allegations

Dr Reddy's Labs acquiring products but not marketing most of them

In 5 of 9 asset buys made in 2014-16, Dr Reddy's is yet to put them to use; it spent Rs 38.82 bn on the acquisitions

Dr Reddy's falls for fourth straight day on poor Q3 results

The stock was trading 3.4% lower at Rs 2,233, down 13% in past four trading days from Rs 2,562 on January 24, as compared to 0.67% decline in the S&P BSE Sensex.

Dr Reddy's Labs Q3 net profit drops 29%; Dalal Street still awaits triggers

Resolution of warning letters issued by FDA and clarity on launches key

Dr Reddy's Q3 profit down 29% at Rs 3.3 bn on higher price erosion

BS ReporterHyderabad, 25 January: Indian pharmaceutical major Dr Reddy's Laboratories Limited has reported a 29 percent decline in consolidated net profit at Rs 3.34 billion for the quarter ended December 2017 on the back of higher price erosion, increased competition and the impact of adverse foreign exchange in the US and European markets.However, the company was able to post a 3 percent increase in consolidated revenues at Rs 38.06 billion during the third quarter under review as compared with Rs 37.07 billion in the corresponding quarter previous year. "We had a satisfactory third quarter performance with all our key markets performing well. We recorded sequential revenue growth of 7 percent despite continuing challenges such as price erosion in the USA. Our first-cycle NDA approval of Impoyz is a significant milestone in the commercialisation o four proprietary products pipeline. We will continue our focus on operational excellence and controlling of SG&A(selling, general and

Dr Reddy's Q3 profit tumbles 38% as sales decline on US pricing pressure

Net profit was Rs 3.03 billion in the third quarter ended December 31

Dr Reddy's falls on buzz of issues raised in EIR for Duvvada plant

The stock dipped 4.5% to Rs 2,299 on the BSE in intra-day trade.

Dr Reddy's settles blister package case with US govt for $5 mn

BS ReporterHyderabad, 19 December: Indian drug major Dr Reddy's Laboratories Limited has reached a settlement with the US Government agencies for $ 5 million in a six year old case regarding complaints of potential harm from the package of blister-packed prescription products to children.In June last year US Consumer Product Safety Commission(CPSC) has requested the US Department of Justice to impose civil penalty on Dr Reddy's for alleged violations of provisions related to child resistant packaging in at least five prescription drugs.While disagreeing with these allegations, the company on Tuesday said it has chosen to settle the matter in order to avoid any unnecessary costs and the distractions of prolonged litigation. In a joint filing by the parties, Dr Reddy's and the US Department of Justice agreed to the settlement of the action without any adjudication of any issue of fact or law.In an investigation conducted between 2008 and 2012, US CPSC held that the company sold ...

Plant clearance removes overhang for Dr Reddy's

Nod to Bachupally plant raises hopes for clearance of its Srikakulam unit

Dr Reddy's rallies after receiving EIR from USFDA

The stock was trading 3% higher at Rs 2,498, after rallying 10% in intra-day trade as the company received EIR from the USFDA for Vishakhapatnam facility, but the inspection has not closed.

Dr Reddy's prospects hinge on FDA clearances

Non-US geographies grow well in Q2; cost controls support profitability

Dr Reddy's up 4% after receiving EIR from USFDA for Srikakulam Unit I

In past one month, the stock has outperformed the market by surging 17% as compared to 2% decline in the S&P BSE Sensex